Reponex Pharmaceuticals Aps has a total of 22 patent applications. It increased the IP activity by 100.0%. Its first patent ever was published in 2012. It filed its patents most often in United States, WIPO (World Intellectual Property Organization) and EPO (European Patent Office). Its main competitors in its focus markets pharmaceuticals and biotechnology are SEANERGY DERMATOLOGY LTD, ZHU LINGXIA and ASYMMETRIC THERAPEUTICS LLC.
# | Country | Total Patents | |
---|---|---|---|
#1 | United States | 11 | |
#2 | WIPO (World Intellectual Property Organization) | 6 | |
#3 | EPO (European Patent Office) | 4 | |
#4 | China | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Biotechnology |
# | Technology | |
---|---|---|
#1 | Medical preparations | |
#2 | Therapeutic chemical compounds | |
#3 | Peptides |
# | Name | Total Patents |
---|---|---|
#1 | Heslet Lars | 22 |
#2 | Uttenthal Lars Otto | 13 |
Publication | Filing date | Title |
---|---|---|
WO2016020530A1 | Compositions for the treatment of periotonitis | |
EP3145533A2 | Compositions for promoting the healing of wounds | |
EP3113789A1 | Compositions for treating lung infections by airway administration | |
CN106163542A | For promoting the compositions of skin ulcer and wound healing | |
WO2015110536A1 | Granulocyte-macrophage colony-stimulating factor for the treatment and prevention of severe forms of bronchial asthma | |
US2016000875A1 | Gm-csf for treatment of chronic oral mucositis | |
EP2694093A2 | Granulocyte-macrophage colony stimulating factor for enhancing pulmonary host defense in acute and chronic radiation syndrome, therapeutic radiation intervention and cancer therapy |